drugset / Trial / NCT02105675
Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care therapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer
Timeline
- Start
- 2012-02
- Primary completion
- 2014-03
- Completion
- 2017-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | — | — |
| Subject | STAPULDENCEL | Vaccine | — | — |